19/11/2024
🚀 Epiprotect Sales Set to Triple in 2024!
We’re excited to share that Epiprotect, developed by S2Medical and powered by our strategic partner, is projected to achieve triple sales growth in 2024, with secured revenue already exceeding SEK 9 million!
Starting in 2024, our royalty model— 2% of sales revenue and 10% of net profit —provides a stable foundation for long-term growth in the multi-billion-dollar wound care market.
This success accelerates the commercialisation of our other innovative solutions:
AMP technologies – antimicrobial peptides
IvaQ – advanced negative pressure wound therapy
Instagraft – efficient skin grafting
Through our partner’s global network, we’re expanding into new markets and strengthening our leadership in wound care. Stay tuned for more updates as we continue to transform healthcare!
For more information, visit our website:
www.s2m.se
